These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30906972)

  • 1. Why is There Discordance between the Reimbursement of High-Cost 'Life-Extending' Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia.
    Saing S; van der Linden N; Hayward C; Goodall S
    Appl Health Econ Health Policy; 2019 Aug; 17(4):421-431. PubMed ID: 30906972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.
    Clegg AJ; Scott DA; Loveman E; Colquitt J; Hutchinson J; Royle P; Bryant J
    Health Technol Assess; 2005 Nov; 9(45):1-132, iii-iv. PubMed ID: 16303098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
    Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
    Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement.
    Messori A; Trippoli S; Bonacchi M; Sani G
    J Thorac Cardiovasc Surg; 2009 Aug; 138(2):480-5. PubMed ID: 19619799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with ventricular assist device use in children.
    Mahle WT; Ianucci G; Vincent RN; Kanter KR
    Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The political economy of the assessment of value of new health technologies.
    Karnon J; Edney L; Afzali H
    J Health Serv Res Policy; 2018 Apr; 23(2):116-122. PubMed ID: 29320891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
    Cleemput I; van Wilder P; Huybrechts M; Vrijens F
    Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
    Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
    Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and reimbursement gaps after implementation of third-generation left ventricular assist devices.
    Mishra V; Geiran O; Fiane AE; Sørensen G; Andresen S; Olsen EK; Khushi I; Hagen TP
    J Heart Lung Transplant; 2010 Jan; 29(1):72-8. PubMed ID: 19783175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic content in medical journal advertisements for medical devices and prescription drugs.
    Ackerly DC; Glickman SW; Schulman KA
    Pharmacoeconomics; 2010; 28(5):429-38. PubMed ID: 20402543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
    Lee SS; Salole E
    Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
    McRae I; van Gool K; Hall J; Yen L
    Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The increasingly complex fourth hurdle for pharmaceuticals.
    Cohen J; Stolk E; Niezen M
    Pharmacoeconomics; 2007; 25(9):727-34. PubMed ID: 17803332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.